Work

Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

Year: 2019

Type: article

Abstract: arsenic and venetoclax could synergistically induce AML cell apoptosis in vitro, which needs to be further validated.According to the MRD results of our two patients, it seems that only one cycle of arsenic and venetoclax combination therapy was capable of inducing a similar response to that observed in the second case, which added oral arsenic after the first cycle of venetoclax monotherapy.In theory, the combined use of arsenic and venetoclax may be better considering the synergistic induction of apoptosis by the two drugs.Our study provided preliminary evidence to support the combination of venetoclax and arsenic in the treatment of NPM1-mutated AML.Because oral arsenic is commercially available in China, a completely oral, chemotherapy-free induction regimen (ie, oral arsenic and venetoclax) in NPM-mutated AML seems worthy of investigation in the future.

Source: American Journal of Hematology

DOI: 10.1002/ajh.25690